What is Lifesci Capital’s Estimate for OLMA FY2025 Earnings?

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) – Research analysts at Lifesci Capital issued their FY2025 earnings per share estimates for Olema Pharmaceuticals in a report released on Wednesday, November 13th. Lifesci Capital analyst S. Slutsky anticipates that the company will post earnings of ($2.12) per share for the year. The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.32) per share.

Other equities research analysts also recently issued research reports about the company. JPMorgan Chase & Co. cut their price objective on Olema Pharmaceuticals from $33.00 to $31.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Oppenheimer reiterated an “outperform” rating and issued a $30.00 price objective on shares of Olema Pharmaceuticals in a report on Wednesday, August 7th. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Olema Pharmaceuticals in a report on Wednesday. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, Olema Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $27.00.

Olema Pharmaceuticals Trading Down 12.0 %

OLMA stock opened at $10.10 on Friday. The company has a market capitalization of $578.73 million, a PE ratio of -4.61 and a beta of 2.02. Olema Pharmaceuticals has a 12-month low of $8.51 and a 12-month high of $17.23. The business’s fifty day moving average price is $12.05 and its 200 day moving average price is $11.96.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.01).

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Point72 Asset Management L.P. acquired a new position in shares of Olema Pharmaceuticals during the 2nd quarter worth about $34,753,000. Janus Henderson Group PLC boosted its position in shares of Olema Pharmaceuticals by 74.5% in the 1st quarter. Janus Henderson Group PLC now owns 1,221,662 shares of the company’s stock valued at $13,817,000 after purchasing an additional 521,562 shares during the period. Candriam S.C.A. boosted its position in shares of Olema Pharmaceuticals by 199.9% in the 2nd quarter. Candriam S.C.A. now owns 1,058,673 shares of the company’s stock valued at $11,454,000 after purchasing an additional 705,655 shares during the period. Great Point Partners LLC boosted its position in shares of Olema Pharmaceuticals by 25.5% in the 3rd quarter. Great Point Partners LLC now owns 1,000,000 shares of the company’s stock valued at $11,940,000 after purchasing an additional 203,120 shares during the period. Finally, Victory Capital Management Inc. boosted its position in shares of Olema Pharmaceuticals by 9.9% in the 3rd quarter. Victory Capital Management Inc. now owns 851,512 shares of the company’s stock valued at $10,167,000 after purchasing an additional 76,720 shares during the period. 91.78% of the stock is owned by institutional investors and hedge funds.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.